Latest News about Biotech
Recent news which mentions Biotech
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
August 01, 2024
From Benzinga
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales
August 01, 2024
From Benzinga
From Benzinga
Moderna Stock Sinks On Lowered 2024 Outlook, Cites Low European Sales, Competitive RSV Vaccine Market
August 01, 2024
From Benzinga
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
August 01, 2024
From Benzinga
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
August 01, 2024
From Benzinga
Cannabis In The Deep South: This Mississippi Company Delivers More Bud For The Buck To Medical Marijuana Patients
August 01, 2024
From Benzinga
Exact Sciences Stock Climbs After Strong Q2 Results
July 31, 2024
From Benzinga
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
July 31, 2024
From Benzinga
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
July 31, 2024
From Benzinga
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
July 31, 2024
From Benzinga
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program
July 31, 2024
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free